NCT01799954View on ClinicalTrials.gov

Evaluating the Safety and Priming Response of an HIV Vaccine Regimen in Healthy, HIV-Uninfected Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
HIV Infections
Interventions
BIOLOGICAL

DNA-HIV-PT123

4 mg of DNA encoding clade C ZM96 Gag and gp140, CN54 Pol-Nef, administered intramuscularly (IM)

BIOLOGICAL

NYVAC-HIV-PT1

(along with NYVAC-HIV-PT4); ≥ 5x106 PFU encoding clade C ZM96 gp140 and ZM96 Gag and CN54 Pol-Nef, administered IM

BIOLOGICAL

NYVAC-HIV-PT4

(along with NYVAC-HIV-PT1); ≥ 5x106 PFU encoding clade C ZM96 gp140 and ZM96 Gag and CN54 Pol-Nef, administered IM

BIOLOGICAL

AIDSVAX® B/E

300mcg of subtype B (MN) HIV gp120 glycoprotein and 300mcg of subtype E (A244) HIV gp120 glycoprotein absorbed onto 600mcg of aluminum hydroxide gel adjuvant, administered IM.

BIOLOGICAL

Placebo for DNA/NYVAC

Sodium Chloride for injection, 0.9% administered IM

BIOLOGICAL

Placebo for AIDSVAX(R) B/E

600 mcg of aluminum hydroxide adjuvant, administered IM

Trial Locations (1)

1011

HVTN Clinical Research Site (HVTN CRS) ,, Lausanne

All Listed Sponsors
lead

HIV Vaccine Trials Network

NETWORK

NCT01799954 - Evaluating the Safety and Priming Response of an HIV Vaccine Regimen in Healthy, HIV-Uninfected Adults | Biotech Hunter | Biotech Hunter